Department of Clinical Epidemiology and Biostatistics, University of Amsterdam, Amsterdam, The Netherlands.
Division of Public Health, Austrian Agency for Health and Food Safety, Vienna, Austria.
Clin Microbiol Infect. 2019 Jan;25(1):54-59. doi: 10.1016/j.cmi.2018.06.011. Epub 2018 Jun 12.
The development of an in vitro diagnostic test from a good idea to a clinically relevant tool takes several steps, with more stringent requirements at every step.
This article aims to summarize the necessary questions to be asked about a test and to illustrate study designs answering these questions. We also aim to relate Regulation (EU) 2017/746 to the needs of evidence-based diagnostic testing, where applicable.
We used literature on evidence-based diagnostics, a text book on clinical trials in the development and marketing of medical devices and the English version of Regulation 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices.
The combination of different test uses and different stages of development determine the required test characteristics and suitability of study designs. In an earlier stage of test development it may be crucial to know whether a test can differentiate diseased persons from healthy controls, although this tells us little about how a test will perform in practice. Later stages focus on the diagnostic accuracy of a test in a clinically relevant situation. However, a test that perfectly distinguishes between patients with and without a certain condition may still have little effect on patient outcomes. Therefore, randomized controlled trials of testing may be needed, as well as post-marketing monitoring.
Both researchers and users of tests need to be aware of the limitations of diagnostic test accuracy and realize that accuracy is only indirectly linked to people's health status.
从一个好的想法到具有临床相关性的工具,体外诊断测试的开发需要经过多个步骤,每个步骤的要求都更加严格。
本文旨在总结需要询问测试的必要问题,并举例说明回答这些问题的研究设计。我们还旨在将(欧盟)2017/746 号法规与基于证据的诊断测试的需求联系起来(在适用的情况下)。
我们使用了循证诊断学文献、一本关于临床试验的医疗器械开发和营销的教科书以及欧洲议会和理事会关于体外诊断医疗器械的 2017/746 号法规(英文版本)。
不同测试用途和不同开发阶段的组合决定了所需的测试特性和研究设计的适用性。在测试开发的早期阶段,了解测试是否可以将患病者与健康对照者区分开来可能至关重要,尽管这对测试在实际中的表现几乎没有什么帮助。后期阶段侧重于测试在临床相关情况下的诊断准确性。然而,一个能够完美区分患有特定疾病和不患有特定疾病的患者的测试,可能仍然对患者的结果影响不大。因此,可能需要进行测试的随机对照试验,以及上市后监测。
测试的研究人员和使用者都需要意识到诊断测试准确性的局限性,并认识到准确性与人们的健康状况仅间接相关。